T his symposium captures the best papers presented at the 2013 meetings of the Musculoskeletal Tumor Society in San Francisco, CA, USA and the International Society of Limb Salvage (ISOLS) in Bologna, Italy. Most of the researchers at the conferences presented clinical and reported outcomes studies based on diagnosis, treatment, or reconstructive method. Pietro Ruggiero, the ISOLS host, ambitiously subtitled the Congress, ''Common Language for the New Century.'' It was a worthy goal, and fulfilled former CORR 1 Editor-in-Chief Richard Brand MD's desire to update and improve our staging and outcome reporting systems. The plenary lectures ''Functional Evaluations Systems,'' by Mark Scarborough MD and ''Modern Assessment of Surgical Margins'' by Fran Hornicek PhD, MD were provocative and offered comprehensive discussions of the topics, setting the stage for thoughtful reevaluation of our methods to assess clinical outcomes.
Most researchers at the meeting used conventional outcome measures. A few individual investigators tried to bring a fresh look at outcomes using different measures, such as postsurgical ambulatory activity level and patientreported quality of life assessments. Still, no system was clearly accepted by the meeting participants. There would be no better way to pay tribute to the recently departed William F. Enneking MD, who championed the systems we currently use, than by continuing to study this essential issue.
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addresses an actionable target to improve cure rates. Since we are no longer answering the ''dead or alive question,'' what are the relevant outcomes in oncology and how do we measure them?
Well-meaning observers can differ even on such basic points as what constitutes outcomes research, particularly with regard to establishing the appropriate balance of clinicianderived, more quantitative performance-based measures with patientreported functional assessments and quality of life. Nevertheless, we all agree that outcomes are important to the patient, surgeon, researcher, institution, and society. They are how we grade ourselves. Outcome measures are also the currency of professional communication. Only in this way can we identify problems, assess quality, document improvement in care for our patients, and compare results across geographic, demographic, and cultural differences.
Several novel measures of postoperative function and quality of life were used, and it will be interesting to see how these methods are accepted in future investigations. Creative efforts to incorporate more comprehensive, better validated outcome measures into the posttreatment assessments of our orthopaedic oncology patients are commendable and merit further exploration. The challenge remains for all investigators worldwide to improve the comprehensiveness and relevance of our measures of quality of life while we continue to work to improve patient survival from musculoskeletal sarcoma.
